OLFM4 and NANOG could be positive and negative predictive markers, respectively, for eradication therapy efficacy against gastric MALT lymphoma that is negative for both API2-MALT1 and Hp infection. This evidence concerns the gene NANOG and gastric mucosa-associated lymphoid tissue lymphoma.